A variety of instruments have been developed to measure the Type A behavior pattern (TABP), although concern has often been expressed that no single measure captures the complete range of attributes encompassed by the notion of the TABP. This paper presents data using a broad range of these instruments applied to a large sample of men at risk of coronary heart disease (CHD). The data indicate considerable variation in strengths of association between measures of the TABP, and recommend three conclusions. Firstly, the TABP is a complex phenomenon and not a unitary one. Secondly, self-report measures of the TABP assess only parts of the overall behavior pattern, and this varies from one instrument to another. Thirdly, the Structured Interview (SI), insofar as it relates modestly and consistently to other instruments, remains the first measure of choice for the TABP. The need to develop new measures, however, seems strongly indicated.
It has been suggested that under normal conditions, there is no relationship between decision and movement time components of response latency. However, for normal Ss, induced elevation of decision time produces conpensatory reductions in movement time. Psychomotor retardation, commonly observed in depressive patients, shows in the main, elevations for decision time. Such patients should also produce compensatory reductions in movement time. This was found not to be so. While 15 controls exhibited no relationship between decision and movement times, 30 depressive Ss exhibited a positive one. The result was discussed in terms of a post hoc postulate of motivational deficit among depressive patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.